In the last five years we have received funding from:

  • Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
(2023-2026) CCQ Accelerating Collaborative Cancer Research
  • Radiomics analysis to improve outcomes for melanoma patients

(2023-2024) Cancer Australia, PdCCRs awarded to Dr Lauren Aoude

  • Understanding predisposition to Oesophageal Adenocarcinoma through defects in DNA damage repair genes

(2023) Cure Cancer EMCR grant awarded to Dr Lauren Aoude

  • Investigating the spatial and temporal tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma

(2022–2023) Cancer Australia, PdCCRs awarded to Dr Sandra Brosda

  • Investigating tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma

(2022-2023) SERTA, Metro South research support scheme

  • Improving outcomes for patients with melanoma brain metastases

(2020-2025) Civic Solutions: Community Skilling & Disability Support Service Inc

  • Blood biomarkers to predict recurrence in BRAF-negative melanoma patients

(2020-2022) Queensland Health Clinical Advance Fellowship

(2020-2022)  PA Research Foundation

  • Role of Complement C3a and neutrophils in melanoma

(2020-2023) NHMRC Development Grant with Dr Barbara Rolfe (UQ)

  • Statins as a potential therapeutic agent for Melanoma

(2018-2019) Australian Skin and Skin Cancer Research Centre (ASSC), Grant with Dr Jason Lee (QIMR Berghofer)

  • Genomics and biological correlates of radiomics in melanoma

(2018-2019) Cure Cancer Australia PdCCRS awarded to Dr Lauren Aoude

  • Improving oesophageal adenocarcinoma outcomes through understanding genomics and treatment toxicity: genomic analysis of the DOCTOR trial

(2018-2020) NHMRC Project Grant with Dr Nic Waddell (QIMR Berghofer)

  • mFOLFIRINOX And STEreotactic body Radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG)

(2018-2023) MRFF clinical trial

  • Tumour neo-antigen-specific immune responses in oesophageal cancer long term survivors: proof-of-concept for improved personalised therapeutic strategies

(2019-2020) Metro South Health Research Support Scheme Program Grant.

  • Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

(2019-2020) Avner Foundation with Dr John Hooper (Mater Research)

  • ctDNA: Towards biomarkers of progression and prognosis in Oesophageal Cancer

(2018-2019) Roche Diagnostics